BMRN
$88.27
Biomarin Pharmaceuticals
($.86)
(.96%)
BMRN
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.03
Revenue:  $462.38 Mil
Thursday
Feb 20
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, October 23, 2019

What do you expect when BMRN reports earnings?
Beat
Meet
Miss

Where is BMRN's stock price going from here?
Up
Flat
Down
Stock chart of BMRN
Analysts
Summary of analysts' recommendations for BMRN
Score
Grade
Pivots
Resistance
$91.01
$90.30
$89.29

$88.58

Support
$87.57
$86.86
$85.85
Tweet
Growth
Description
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Peers
Regeneron PharmaceuticalsInterCeptVertex PharmaceuticalsMylanZoetisJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEndo International plcGlaxoSmithKline plc